Single oral dose ondansetron in the prevention of postoperative nausea and emesis

Rust, Meinhard; Cohen, L. A.

doi:10.1111/j.1365-2044.1994.tb03578.x

Cited by 64 publications

(26 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dizziness has also been reported in phase I (13%) and phase II (5%) dolasetron studies as well as following a single oral dose of ondansetron for the prevention of emetic symptoms (3.4%). 19 Droperidol, ondansetron, granisetron, transdermal scopolamine, and most recently perphenazine 23 are effective in preventing PONV. In that recent study, droperidol, ondansetron, and perphenazine were equally effective in reducing PONV for the first four hours after surgery but the authors concluded that perphenazine was the drug of choice because of its low cost and low incidence of side-effects.…”

Section: Discussionmentioning

confidence: 99%

“…Complete responses for the prevention of PONV were 54% in a European study is and 52% in a U.S. study. 19 All 5-HT 3 receptor antagonists prolong intracardiac conduction. Batanopride (BMY-25801), a 5-HT 3 receptor antagonist investigated as an antiemetic in patients receiving cancer chemotherapy, produced dose-dependent prolongation of QRS and Q-Tc at doses required for antiemetic effect.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy

et al. 1997

View full text Add to dashboard Cite

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomyPurpose: The incidence of postoperative nausea and vomiting (PONV) varies from 50% to 75% after g)maecological surgery under general anaesthesia, This study evaluates the dose-response relationships, safety, and eff~cy of the new 5-HT3 antagonist dolasetron mesTiate, in the prevention d PONV in women undergoing total abdominal hysterectomy (TAll), Medmd,: Three hundred and seventy four women scheduled for TAH under general anaesthesia were studied at 13 Canadian centres. Patients received in a randomized, double-blind manner 25, 50, I00, or 200 rr~ do~on or placebopo one to two hours before induction of anaesthesia. The anestf~c protocol was standardized. EtT~acy was evaluated for 24 hr" after surgery by comparing the number of emetic episodes, administration of rescue medication, seventy of nausea, and patient satisfaction. Results: Analysis of complete response (no emetic episodes and no rescue for 24 hr) revealed a linear doseresponse relationship across dolasetron groups (P < 0.002). Dolasetron 100 mg (P < 0.003) and 200 mg (P < 0.0 I) were superior to placebo. The percentage of patients with no emetic episodes increased from 29.3% (placebo) to 54. 1% (100 rng). Subgroup analysis revealed ASA status (1>11), previous history of PON~, previous history of motion sickness, and total morphine dose (>55 rng assodated with less PONV than < 55 rag) influenced the incidence of emetic symptoms, but did not alter the results of the primary analysis. Conclusion: Prophylactic dolasetron ( 100 rng and 200 rag) reduces the incidence of PONV in patients having total abdominal hysterectomy.Obj~'tis : Apr~ une intervention ~:ologique sous anesth~ie g~rale, l'inddence des naus~s et des vormssements postol~ratoires (NVPO) varie de 5096 .~ 75%. Cette ~tude L%alue la relation dose-effet, la s&uritE et l'e$cacitd d'un nouvel an~oniste 5-HT 3, le ~ate de dolasetron, lorsque administr~ pour prCr'venir les NVPO chez des femrnes soumises ~ une hyst~rectornie abdominale totale (HAT). ML'thod~ : Trois cent soixante-quatorze femmes p~rn~ pour une HAT sous aneslf~e gL'~mle ont partidp~ l'~'tude dam 13 centres canadiens. Les patientes ont regJ en double aveugle et al~atoirernent 25, 50, 100 et 200 rng de dolasetron ou un placebo po une ou deux heures avant l'induc~on de l'anesth~ie selon un protocole standard. Ce$cacit~ a L,~ ~valu~e pendant 24 h apr~s la chiru~e en comparant le nombre d'Episodes A..rncedclues, l'admini~isdi~n d'un rnckJicament de sauvet,Ee, la om-avitE des nausL, es et le de~ de satisfaction. ][~tats : Canalyse de l'effet maximal (absence d'~pisodes (~rn~ques et abstention de rn~licament de sauvet~ pendant 24 h) a r~v~l~ une relation dose-effet lir~aire pour les ~'oupes dolasetron (P < 0,002). Le dolaseron aux doses de 100 rr~ (P < 0,003) et de 200 mg (P < 0,0 I) ~ sup~rleur au placebo. Le pourcenta~ des patientes sans Episode ~rn~que augrnentait de 29,3% (placebo) ~ 54, 1% (I00 rag). Une analyse de sous-~:~Jpe montrait que l'Eta...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Its use in the prevention and treatment of PONV is relatively new and optimal administration times have yet to be determined (Dupeyron et al, 1993;Rust & Cohen, 1994).…”

Section: Resultsmentioning

confidence: 99%

There is no Difference in the Incidence of Postoperative Nausea and Vomiting (PONV) When Ondansetron (ZOFRAN) is Administered Prior to Induction or Emergence from General Anesthesia

Peuterbaugh¹,

West²

1997

View full text Add to dashboard Cite

Public reporting burdan for tNs collection of information is estimatetl to average 1 hour per response, inclurling the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. ABSTRACT (Maximum 200 words)The purpose of this study was to determine if ondansetron is more effective in the prevention of PONV when administered prior to induction versus prior to emergence from general endotracheal anesthesia. This was a prospective, randomized, double-blind study of ASA I-III patients. Group I received ondansetron at induction (n=75) and Group II received ondansetron at emergence (n=75). A general anesthesia protocol was followed and data was collected in the recovery room and at 24 hours. Group I had a 28.1% incidence of nausea m the PACU and 1.2 hours of nausea for the 24 hours post emergence, while Group II had a 23.4% incidence in the PACU and 1.5 hours respectively. Vomiting in the PACU for the Group I was 4.8% and 25% at 24 hours post emergence. Group II had a 1.6% incidence of vomitmg m the PACU and 14 % at 24 hours. No significant difference was found between these two groups of mostly of female patients. When ondansetron 4 mg IV is administered at induction or emergence from general endotracheal anesthesia, patients experience a similar incidence of PONV in the recovery room and up to 24 hours post emergence.

show abstract

“…São, todavia, relativamente poucos os estudos que tratam da eficá-cia da ondansetrona oral na prevenção de NVPO 6,7,[112][113][114][115][116][117] . No presente estudo, buscou-se confirmar a eficácia da administração oral pré-operatória deste fármaco em intervenções com duração não superior a 3 horas.…”

Section: Discussionunclassified

“…Assim, a disponibilidade de 16 mg deste fármaco após a administração oral equivale a 8 mg em injeção intravenosa 108 . Em razão do exposto, nesta investigação optou-se por veicular a ondansetrona em comprimidos de dissolução instantânea e definiu-se 16 mg de ondansetrona, dose que se mostrou efetiva no presente estudo e em outros encontrados na literatura 112,114,116 .…”

Section: Discussionunclassified

Ondansetrona oral na prevenção de náuseas e vômitos pós-operatórios

Lewaschiw¹,

Pereira²,

Amaral³

2005

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

35 ONDANSETRONA ORAL NA PREVENÇÃO DE NÁUSEAS E VÔMITOS PÓS-OPERATÓRIOSRESUMO -OBJETIVOS. Em passado não remoto, a incidência de náuseas e vômitos no pós-operatório (NVPO) ainda alcançava 40% a 50%. Publicações mais recentes indicam que a freqüên-cia desta complicação ainda é considerável: 20% a 30%. O presente estudo teve como objetivo avaliar, em pacientes submetidos à anestesia geral, o impacto da administração oral de ondansetrona na incidência de NVPO.MÉTODOS. Foram incluídos 178 pacientes em estudo prospectivo, randomizado, controlado e duplo-cego, divididos em dois grupos (ondansetrona=89 e placebo= 89), utilizandose comprimidos de dissolução oral rápida, especialmente preparados para este estudo. A medicação foi administrada entre 30 e 60 minutos antes da indução anestésica. Anotou-se fatores que pudessem influenciar o evento, como gênero, idade, antecedentes de discinesia ou NVPO, tabagismo, tipo de cirurgia, INTRODUÇÃONáuseas e vômitos no pós-operatório (NVPO) -fenômenos referidos como "os grandes pequenos problemas" 1 -em passado não remoto alcançavam elevada incidência: 28,5% a 80% para náuseas e 50% a 66% 2,3 para vômitos. Publicações mais recentes indicam que a freqüência desta complicação ainda é considerável: 20% a 30% 4,5 , podendo atingir 54% em amigdalectomias infantis 6 e variando de 50% a 56% em procedimentos laparoscópicos 7,8,9 . Este fato deve-se provavelmente ao impacto positivo de mudanças na prática anestésica. Aqui, entre outros avanços relevantes, destacam-se a atenção ao controle da ansiedade pré-operatória, a analgesia pós-operatória e a introdução de novos agentes anestésicos. Ainda assim, e, sobretudo na presença de fatores predisponentes, justifica-se considerar a administração profilática de antieméticos.Durante anos, NVPO foram considerados efeitos inerentes à aplicação de anestésicos ou , bem como diversos agentes farmacoló-gicos como os fenotiazínicos proclorperazina [20][21][22] , prometazina [23][24][25] e perfenazina 26,27 ; os butirofenônicos haloperidol [28][29][30][31] e droperidol 25,[32][33][34][35][36][37][38][39] ; os anti-histamínicos difenidramina (dimenidrato) 40,41 ; hidroxizina 42,43 e ciclizina 4447 ; dentre os anticolinérgicos, a escopolamina 23,4850 ; os benzamídicos como a metoclopramida 33,37,[51][52][53][54][55][56][57] e domperidona 33,37,[58][59][60][61] ; a alizaprida [62][63][64][65] ; os corticosteróides 33,[66][67][68][69][70][71][72][73][74][75][76] ; a efedrina 77 ; o propofol [78][79][80][81][82][83][84] ; os antiserotoninérgicos ondansetrona 8,13,20,39,41,45,46,56,81,[85][86][87][88][89][90][91][92][93][94][95][96][97] , a granisetrona , encontra-se entre os agentes mais largamente empregados no controle de NVPO. Apesar de apresentar resultado mais eficaz que a metoclopramida 3,7,13,56,85,87,91,105 , o custo elevado das preparações intravenosas de ondansetrona tem ainda limitado sua utilização 81,106,107 . Assim, considerando as características farmacocinéticas favoráveis 108,109 , o menor custo e a conveniência da administração oral, busca-s...

show abstract

Single oral dose ondansetron in the prevention of postoperative nausea and emesis

Cited by 64 publications

References 7 publications

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy

There is no Difference in the Incidence of Postoperative Nausea and Vomiting (PONV) When Ondansetron (ZOFRAN) is Administered Prior to Induction or Emergence from General Anesthesia

Ondansetrona oral na prevenção de náuseas e vômitos pós-operatórios

Contact Info

Product

Resources

About